STAT+ reported that Oura’s planned acquisition of telehealth startup Counsel Health is raising potential conflict-of-interest questions for Eli Lilly, as Lilly has previously promoted Counsel on GLP-1 prescription provider lists. The deal would expand Counsel clinicians’ access to smart-ring data, potentially tightening the data loop used in diagnosis or treatment decisions. The concern is less about the clinical utility of wrist or ring telemetry and more about how commercial relationships evolve when a pharma-backed care channel gains a new data pipeline. For industry, it underscores how device-mediated care can blur provider, platform, and sponsor boundaries.